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154
of longitudinal data confirmed that GMV differences were unlikely to precede cannabis use.
155
GMV in the temporal regions was associated with contemporaneous performance on the
156
Perceptual Reasoning Index and with future generalized anxiety symptoms in the cannabis 157 users. The distribution of GMV effects mapped onto biomarkers of the endogenous cannabinoid 158 system providing insight into possible mechanisms for these effects.
160
Significance Statement 
190
One study has reported differences in grey matter density and shape of the amygdala and 
195
One mechanism by which cannabis may produce neurobiological changes is through the 
209
In the present study we identified participants with just one or two instance of cannabis use from 210 a very large, population sample of adolescents (IMAGEN, n = 2400 (Schumann et 
219
To test whether observed differences between cannabis users and controls may precede 220 cannabis use, we also identified participants who were cannabis-naïve at the time of imaging 221 but went on to use cannabis two years later and matched controls who remained abstinent.
222
Finally, in order to demonstrate association with the eCB system, we compared the spatial 223 distribution of GMV effects with two biomarkers of the eCB system using CB 1 receptor 224 availability taken from a previously published, independent sample ( ) and 225 the expression of the CNR1 gene, which encodes this receptor, taken from the Allen Human
226
Brain Atlas (Hawrylycz et al., 2012) . 
227

Materials and Methods
228
254
For a subset of the 14-year-old cannabis-using participants, data were available at two-year
255
follow-up for substance use, cognitive ability, and psychopathology at age 16 to allow us to 256 assess the implications of cannabis-related GMV differences for future functioning in these 257 domains. 
268
We again ensured that similar numbers of cannabis users and controls were selected from each 269 site (Mann-Whitney U tests, Table 3 ) and confirmed that the proportion of cannabis users and 270 controls did not differ by site using a Kruskal-Wallis Test ( 2 (7) = 4.633, p = 0.705).
272
For both cohorts, the control subjects were selected from a larger pool of IMAGEN participants 
306
Demographic Measures
307
Biological sex was determined by karyotype analysis (chromosome 23: XX=female, XY=male).
308
Participants provided blood samples, which were shipped to the Institute of Psychiatry, London
309
for genotyping with Illumina Human610-Quad Bead Chips (Illumina, San Diego, CA, USA). DNA 
322
Physical maturity was assessed using the Pubertal Development Scale (Petersen et 
344
Psychomotor speed and manual dexterity were assessed using the Perdue Pegboard (Tiffin, 
349
Spatial working memory and decision-making were assessed using the Cambridge
350
Neuropsychological Test Automated Battery (CANTAB (Robbins et al., 1994) 
415
We also conducted region-of-interest analyses in cohort 2 in which we extracted GMV from the
416
regions showing significant volume differences between baseline users and controls to confirm 417 that GMV differences in these specific regions did not precede cannabis use. Note that these 418 regions were defined by the analysis of cohort 1 (n = 46), and then tested on an independent 419 cohort (cohort 2, n = 69).
421
A series of post hoc analyses were conducted to ensure that group differences in GMV between 422 baseline users and controls could not be accounted for by any differences in cognitive ability, 
487
Of all the variables describing cognitive ability, symptoms of psychopathology, and personality, 
494
cluster centered on the left inferior temporal gyrus (Table 6 ) was also revealed in this analysis
495
as showing significantly greater GMV in the cannabis users than the controls.
497
Cohort 1: Associations Between GMV and Contemporaneous Behavioral Measures
498
In light of the individual differences in normalized GMV effects in the cannabis using group, we 
509
The cannabis use metrics (age of use or whether cannabis was used in the last month) were not 510 associated with GMV.
512
Of the specific cognitive and psychological domains assessed at baseline, only psychomotor 
517
Cohort 2: Associations Between GMV and Future Cannabis Use
518
There were no regions at which GMV differed between the future cannabis users and their 519 matched controls. Region of interest analyses focused on those regions from cohort 1 that 520 differed between baseline users and matched controls also revealed no significant differences 521 between future cannabis users and matched controls (Table 7) . 
523
541
Cohort 1: Spatial Associations Between GMV Effects and CNR1 Gene Expression
542
Comparison of the t-statistic map of GMV differences between cannabis users and controls with 
547
Discussion
548
We present evidence of GMV differences in adolescents associated with only one or two 
553
GMV increases were also observed in the lingual gyri, posterior cingulate, and cerebellum. The 
566
Converging evidence suggests that these effects may be a consequence of cannabis exposure.
567
GMV differences could not be explained by group differences in demographic, personality,
568
psychopathology, or other substance use factors. Examination of THC-naïve 14 year olds who 569 later used cannabis showed no GMV differences, even using a more liberal regions of interest 570 test, suggesting that the differences do not precede cannabis use and are not due to 571 unidentified factors in those predisposed to use. Finally, the spatial distribution of GMV effects 572 was associated with the eCB system, suggesting cannabis exposure may cause these findings.
573
The preclinical literature presents a number of possible mechanisms by which low levels of 574 cannabis exposure could result in greater GMV relative to THC-naïve controls. Adolescent rats 575 treated with cannabinoid agonist showed altered gliogenesis in regions including the striatum 576 and greater preservation of oligodendroglia relative to control animals (Bortolato et al., 2014) .
577
Zebra finches treated with cannabinoid agonist showed greater dendritic spine densities (Gilbert
578
and Soderstrom, 2011); critically, these effects were observed in late-prenatal but not adult 
593
were generated in independent samples of adults and may not accurately represent the eCB 594 system in our sample of adolescents. Although we report significant spatial associations 595 between GMV effects and both CNR1 gene expression and CB 1 receptor density, the effect 596 sizes were small and any suggestion that these associations represent mechanisms for the 597 effects we observe is speculative and requires further investigation.
599
We adopted a whole brain, VBM approach to detect effects that were not limited by anatomical 
630
We note individual differences in GMV effects: Although regional GMV was increased at the 631 group level for adolescents with low levels of cannabis exposure, the distributions showed a 632 high degree of overlap such that many cannabis users had GMV equivalent to that of controls.
633
None of the tested demographic, personality, or substance use factors stratified GMV in the 634 cannabis users. We note evidence that an association between cannabis use and cortical
635
thickness was stratified by genetic risk for schizophrenia (French et al., 2015) and that an 636 association between cannabis use and hippocampal shape was stratified by dopamine-relevant 637 genes (Batalla et al., 2018) . Some adolescents may be vulnerable to GMV effects at extremely 638 low levels of cannabis use and it will be critical to identify those at risk as these structural brain 639 changes may be associated with individual risk for psychopathology and deleterious effects on 640 mood and cognition.
641
Of the behavioral variables tested, only sensation seeking and agoraphobia differed between 642 the cannabis users and controls and these factors were not related to GMV differences. In the 643 cannabis using participants, GMV in the medial temporal clusters was associated with PRIQ
644
and psychomotor speed such that greater GMV in these regions was associated with reduced 645 performance. The finding that right medial temporal GMV predicted generalized anxiety 646 symptoms at follow up for those participants who had used cannabis should be interpreted with
647
caution given the small sample size and that we were not able to identify factors that drove the 648 individual differences in cannabis effects on GMV at baseline. These findings are notable,
649
however, as panic and anxiety symptoms are frequently reported side effects by naïve and 650 occasional cannabis users (Hall and Solowij, 1998 
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